Aptorum posts mid‑2025 interim financial report

Aptorum Group Limited submitted a Form 6-K to provide its unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025, along with a related operating and financial review.

Rhea-AI Filing Summary

Aptorum Group Limited submitted a Form 6-K to provide its unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025, along with a related operating and financial review. These materials give an updated picture of the company’s mid‑year financial position and performance.

The company is also incorporating these interim financial statements into its existing Form S-8 and Form F-3 registration statements, so the new information becomes part of those offering documents. The filing further lists key agreements related to its previously disclosed transaction with DiamiR, including a merger agreement, management services agreement, intellectual property license, voting and support agreement, and a form of stockholders agreement, plus the associated Inline XBRL data files.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Aptorum Group Limited (APM) disclose in this Form 6-K?

Aptorum Group Limited furnishes unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025, plus an operating and financial review. It also lists key DiamiR-related agreements and provides Inline XBRL files for structured financial data.

How will the new interim financials affect Aptorum Group Limited (APM) registrations?

The interim financial statements are incorporated by reference into Aptorum’s existing Form S-8 and Form F-3 registration statements. This means current mid‑2025 financial information now forms part of those offering documents and their related prospectuses for investors.

Which DiamiR-related agreements are referenced in Aptorum Group Limited’s (APM) filing?

The filing references a merger agreement, a management services agreement, an intellectual property license agreement, a voting and support agreement with a major shareholder, and a form of stockholders agreement, all dated July 14, 2025 and previously filed on an earlier Form 6-K.

What financial periods are covered by Aptorum Group Limited’s (APM) interim statements?

The unaudited interim condensed consolidated financial statements cover Aptorum’s financial position as of June 30, 2025 and December 31, 2024, and results for the six months ended June 30, 2025 and 2024, giving a comparative mid‑year view across two periods.

What narrative analysis accompanies Aptorum Group Limited’s (APM) interim financials?

Alongside the interim financial statements, Aptorum provides an Operating and Financial Review and Prospects section. This narrative discusses the interim results for the six months ended June 30, 2025 and 2024 in more detail and explains key business and financial developments.

What Inline XBRL materials does Aptorum Group Limited (APM) include in this report?

The filing includes an Inline XBRL instance document and related taxonomy extension files for schema, calculation, definition, label, and presentation. These structured data exhibits support electronic analysis and regulatory consumption of Aptorum’s interim financial information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 04:31 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-38764

Aptorum Group Limited

17 Hanover Square

London W1S 1BN, United Kingdom

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒            Form 40-F  ☐

EXPLANATORY NOTE

Aptorum Group Limited (the “Company”) is furnishing this Form 6-K to provide six-months interim consolidated financial statements ended June 30, 2025 and to incorporate such consolidated financial statements into the Company’s registration statements referenced below.

This Form 6-K is hereby incorporated by reference into the registration statements of the Company on Form S-8 (Registration Number 333-232591) and Form F-3 (Registration Number 333-268873) and into each prospectus outstanding under the foregoing registration statements, to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

1

Financial Statements and Exhibits.

Exhibits.

The following exhibits are attached.

Exhibit		Description
10.1		Merger Agreement by and between Aptorum and DiamiR, dated July 14, 2025 (incorporated by reference to the Curent Report on Form 6-K filed on July 22, 2025)
10.2		Management Services Agreement by and between Aptorum Therapeutics and DiamiR, dated July 14, 2025 (incorporated by reference to the Curent Report on Form 6-K filed on July 22, 2025)
10.3		Intellectual Property License Agreement by and between Aptorum Therapeutics, Aptorum, DiamiR LLC, and DiamiR, dated July 14, 2025 (incorporated by reference to the Curent Report on Form 6-K filed on July 22, 2025)
10.4		Voting and Support Agreement by and between Aptorum and its major shareholder, dated July 14, 2025 (incorporated by reference to the Curent Report on Form 6-K filed on July 22, 2025)
10.5		Form of Stockholders Agreement (incorporated by reference to the Curent Report on Form 6-K filed on July 22, 2025)
99.1		Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2025 and December 31, 2024, and for the Six Months Ended June 30, 2025 and 2024
99.2		Operating and Financial Review and Prospects in Connection with the Unaudited Interim Consolidated Financial Statements for the Six Months Ended June 30, 2025 and 2024
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 3, 2025

	Aptorum Group Limited
	By:	/s/ Ian Huen
		Ian Huen
		Chief Executive Officer

3